Eugia Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EUGIA PHARMA, and what generic alternatives to EUGIA PHARMA drugs are available?
EUGIA PHARMA has one hundred and sixty-nine approved drugs.
There is one US patent protecting EUGIA PHARMA drugs. There are three tentative approvals on EUGIA PHARMA drugs.
There are ten patent family members on EUGIA PHARMA drugs in nine countries and three hundred and fifty-one supplementary protection certificates in eighteen countries.
Summary for Eugia Pharma
International Patents: | 10 |
US Patents: | 1 |
Tradenames: | 143 |
Ingredients: | 135 |
NDAs: | 169 |
Patent Litigation for Eugia Pharma: | See patent lawsuits for Eugia Pharma |
Drugs and US Patents for Eugia Pharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eugia Pharma | PHENYLEPHRINE HYDROCHLORIDE | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 210697-001 | Nov 13, 2020 | AP1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Eugia Pharma | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | POWDER;INTRAVENOUS | 217401-001 | Aug 4, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Eugia Pharma | LENALIDOMIDE | lenalidomide | CAPSULE;ORAL | 213885-005 | Mar 6, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Eugia Pharma | LETROZOLE | letrozole | TABLET;ORAL | 211717-001 | Jan 11, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Eugia Pharma Speclts | AMPICILLIN SODIUM | ampicillin sodium | INJECTABLE;INJECTION | 065499-002 | Aug 17, 2010 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Eugia Pharma | BUPIVACAINE HYDROCHLORIDE | bupivacaine hydrochloride | INJECTABLE;INJECTION | 207183-001 | May 13, 2016 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Eugia Pharma Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20170008252 | ⤷ Sign Up |
Japan | 6516831 | ⤷ Sign Up |
China | 106456654 | ⤷ Sign Up |
Australia | 2015256331 | ⤷ Sign Up |
Brazil | 112016026140 | ⤷ Sign Up |
Japan | 2017514924 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eugia Pharma Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1411918 | 300537 | Netherlands | ⤷ Sign Up | PRODUCT NAME: PLERIXAFOR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX; REGISTRATION NO/DATE: EU/1/09/537/001 20090804 |
0717738 | PA2004004 | Lithuania | ⤷ Sign Up | PRODUCTNAME: LINEZOLIDUM - (S)-N-[[3-FLUOR-4-(4-MORFOLINIL)FENIL]-2-OKSO-5-OKSAZOLIDINIL]METIL]-ACETAMIDAS |
0817775 | 5/2006 | Austria | ⤷ Sign Up | PRODUCT NAME: ERLOTINIB UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE ERLOTINIBHYDROCHLORID; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 - EU/1/05/311/003 20050919; FIRST REGISTRATION: CH 57266 01 - 57266 03 20050321 |
1189916 | 2011C/004 | Belgium | ⤷ Sign Up | PRODUCT NAME: REGADENOSON; AUTHORISATION NUMBER AND DATE: EU/1/10/643/001 20100906 |
2207786 | LUC00326 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COMPOSITION COMPRENANT: DE LA CEDAZURIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; ET DE LA DECITABINE; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230913 |
1746976 | 2017C/027 | Belgium | ⤷ Sign Up | PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.